Abstract
Oncolytic human adenoviruses are envisioned as novel, replication-based treatments for human malignancies but have shown limited clinical efficacy to date as monotherapies. Consequently, the generation of more potent agents is needed. Efforts to create more potent Ads have traditionally been directed towards altering selected viral properties (e.g. efficiency of cell lysis, infectivity, viral DNA replication) or through adding therapeutic genes that complement the lytic function of viruses (armed therapeutic viruses).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
